65 results
8-K
EX-99.1
KYMR
Kymera Therapeutics Inc
2 May 24
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
7:10am
headquarters in Watertown, MA, to support the growing organization and scale critical research and development capabilities to enable the expansion … attributable to the Company’s Sanofi collaboration.
Research and Development Expenses: Research and development expenses were $48.8 million for the first
8-K
EX-99.1
b67vfxyx
22 Feb 24
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
7:10am
8-K
EX-99.2
ee6iip9iyuafnz34kf
5 Jan 24
Kymera Therapeutics Announces Proposed Public Offering
4:11pm
8-K
EX-99.1
9wvvl0ywgg274quxfy0
5 Jan 24
Kymera Therapeutics Announces Proposed Public Offering
4:11pm
424B5
v7bho8h2p2 63l
5 Jan 24
Prospectus supplement for primary offering
4:02pm
424B5
hy75ichek zc
4 Jan 24
Prospectus supplement for primary offering
4:06pm
8-K
EX-99.1
0ogdhw6thnq
4 Jan 24
Regulation FD Disclosure
4:01pm
8-K
sld3bxz uv2tyigi
4 Jan 24
Regulation FD Disclosure
4:01pm
8-K
EX-99.1
dcr5ktt8 obd
2 Nov 23
Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update
7:10am
8-K
EX-99.1
f0o2x5otz s465
3 Aug 23
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
7:10am
8-K
EX-99.1
33iipzq
4 May 23
Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update
7:10am
8-K
EX-99.1
6j7xkh w140
14 Dec 22
Regulation FD Disclosure
9:27am